See the DrugPatentWatch profile for semaglutide

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a medication used to treat type 2 diabetes and, in some countries, for chronic weight management. The drug is marketed under the brand names Ozempic and Rybelsus by Novo Nordisk. As for the patent expiration date of semaglutide, it is essential to understand that patents can cover various aspects of a drug, such as the active ingredient, formulation, and manufacturing methods.

According to DrugPatentWatch.com [1], the basic compound patent for semaglutide expired in the United States in February 2021. However, additional patents related to the formulation, form, and composition of semaglutide in specific drug products, such as Ozempic and Rybelsus, may still be in force. These patents can potentially extend the market exclusivity of these products.

For instance, the Rybelsus (semaglutide oral tablet) formulation patent is set to expire in the US in August 2030 [1]. Meanwhile, the Ozempic (semaglutide injection) formulation patent is expected to expire in the US in July 2031 [1]. It is important to note that these dates are subject to change due to potential patent challenges, extensions, or other factors.

In summary, while the basic compound patent for semaglutide has expired in the US, patents covering specific formulations and drug products are still in force, potentially extending market exclusivity for Novo Nordisk.

Sources:
[1] DrugPatentWatch.com - Semaglutide (Ozempic, Rybelsus) Patents, Generics, and Biosimilars - <https://www.drugpatentwatch.com/drugs/semaglutide>